Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: A randomized, crossover, double-blind study

BMC Pharmacology

Volumn 10, Issue , 2010, Pages

  García García, Idrian ^a   González Delgado, Carlos A ^b   Valenzuela Silva, Carmen M ^a   Díaz Machado, Alina ^b   Cruz Díaz, Marisol ^a   Nodarse Cuní, Hugo ^a   Pérez Pérez, Orlando ^b   Bermúdez Badell, Cimara H ^a   Ferrero Bibilonia, Joel ^c   Páez Meireles, Rolando ^c   Bello Rivero, Iraldo ^a   Castro Odio, Fidel R ^c   López Saura, Pedro A ^a  

^a Center for Biological Research Cuba   (Cuba)

^b Ophthalmological Unit   (Cuba)

^c CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA 2 MICROGLOBULIN; INTERFERON; NEOPTERIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; MESSENGER RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BIOLOGICAL ACTIVITY; CHILL; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; HUMAN; HUMAN EXPERIMENT; HYPERESTHESIA; HYPERTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE WARMTH; LEUKOCYTE COUNT; LEUKOPENIA; LOW BACK PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NEUTROPENIA; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TACHYCARDIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; HALF LIFE TIME; METABOLIC CLEARANCE RATE; METABOLISM; MICROBIOLOGICAL EXAMINATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTIVIRAL AGENTS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LEUKOPENIA; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; NEOPTERIN; POLYETHYLENE GLYCOLS; RNA, MESSENGER; YOUNG ADULT;

EID: 78549288540     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-10-15     Document Type: Article

References (33)

1. Monkarsh SP, Ma Y, Aglione A, Bailon P, Ciolek D, DeBarbieri B, Graves MC, Hollfelder K, Michel H, Palleroni A, Porter JE, Russoman E, Roy S, Pan YC. Positional isomers of monopegylated interferon a-2a: isolation, characterization and biological activity. Analytical Biochem 1997, 247:434-440.
2. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000, 68:556-567. 10.1067/mcp.2000.110973, 11103758.
3. Ferenci P. PEG IFN alfa-2a (40 KD) (Pegasys) for the treatment of patients with chronic hepatitis C. Int J Clin Pract 2003, 57:610-615.
4. Robins GW, Scott LJ, Keating GM. PEG IFN-alpha-2a (40 kD): a review of its use in the management of patients with chronic hepatitis B. Drugs 2005, 65:809-825. 10.2165/00003495-200565060-00010, 15819595.
5. Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-alpha2b: a branched 40 K polyethylene glycol derivative. Pharm Res 2005, 22:1374-1386. 10.1007/s11095-005-5278-4, 16078148.
6. Ferrero J, Duany L, Remón JY, Vega M, López-Saura P. Nuevo programa de cálculo. Cuantificación de la actividad antiviral de interferones mediante la inhibición de efecto citopatogénico utilizando el sistema de equipos SUMA. Biotecnología Aplicada 1997, 14:267-269.
7. Steinijans VW, Hauschke D. Update on the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990, 28:105-110.
8. Steinijans VW, Hauschke D. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990, 28:72-78.
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry Statistical Approaches to Establishing Bioequivalence 2001, 1-45. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry.
10. The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products (CPMP) Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2002, 1-18. London, The European Agency for the Evaluation of Medicinal Products: Committee for Proprietary Medicinal Products (CPMP).
11. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP) Guideline on Similar Medicinal Products Containing Recombinant Interferon Alpha 2007, 1-7. London, European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP).
12. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Duconge J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D 2004, 5:271-280. 10.2165/00126839-200405050-00003, 15357626.
13. Xu ZX, Hoffman J, Patel I, Jonbert P. Single-dose safety/tolerability and pharmacokinetics/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-INF) and interferon α-2a (INF α-2a) to healthy subjects. Hepatology 1998, 28:702A.
14. Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of PEG IFN α-2a (PEG-INF) and may explain its enhanced efficacy in chronic hepatitis C (abst 120). Dallas: American association for the study of liver diseases (AASLD) 1999,
15. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001, 19:1312-1319.
16. Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G. Pharmacodynamics of PEG IFN alpha-2a and PEG IFN alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study. Aliment Pharmacol Ther 2007, 26:369-376. 10.1111/j.1365-2036.2007.03392.x, 17635371.
17. Chen ML, Lesko LJ. Individual bioequivalence revisited. Clin Pharmacokinet 2001, 40:701-706. 10.2165/00003088-200140100-00001, 11707058.
18. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568. 10.1038/nri2314, 2522268, 18575461.
19. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003, 195:346-355. 10.1002/jcp.10290, 12704644.
20. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002, 3:175-187. 10.2174/1389200024605082, 12003349.
21. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 1997, 33:142-152. 10.2165/00003088-199733020-00005, 9260036.
22. Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 2002, 91:18-31. 10.1002/jps.1167, 11782894.
23. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing Biotechnology-derived proteins as active substance: Non-clinical and clinical issues 2006, 1-8. London, European Medicines Agency.
24. Napoli N, Giannelli G, Antonaci A, Antonaci S. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hepat 2008, 15:300-304. 10.1111/j.1365-2893.2007.00944.x, 18307592.
25. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, . IDEAL Study Team Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593. 10.1056/NEJMoa0808010, 19625712, IDEAL Study Team.
26. Gross G, Ikenberg H, Roussaki A, Drees N, Schopf E. Systemic treatment of condylomata acuminata with recombinant interferon-alpha-2a: low-dose superior to the high-dose regimen. Chemotherapy 1986, 32:537-541. 10.1159/000238464, 3802956.
27. Marcellini M, Kondili LA, Comparcola D, Spada E, Sartorelli MR, Palumbo M, Rapicetta M. High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease. Pediatr Infect Dis J 1997, 16:1049-1053. 10.1097/00006454-199711000-00009, 9384338.
28. Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Intermediate dose recombinant interferon - alpha as second - line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer 2000, 89:1490-1494. 10.1002/1097-0142(20001001)89:7<1490::AID-CNCR11>3.0.CO;2-V, 11013362.
29. Boulestin A, Kamar N, Sandres-Sauné K, Alric L, Vinel JP, Rostaing L, Izopet J. Pegylation of IFN-alpha and antiviral activity. J Interferon Cytokine Res 2006, 26:849-853. 10.1089/jir.2006.26.849, 17238827.
30. Corssmit EP, Heijligenberg R, Hack CE, Endert E, Sauerwein HP, Romijn JA. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin Exp Immunol 1997, 107:359-363. 10.1111/j.1365-2249.1997.269-ce1161.x, 1904568, 9030876.
31. Wang YX, Xu WG, Sun XJ, Chen YZ, Liu XY, Tang H, Jiang CL. Fever of recombinant human interferon-alpha is mediated by opioid domain interaction with opioid receptor inducing prostaglandin E2. J Neuroimmunol 2004, 156:107-112. 10.1016/j.jneuroim.2004.07.013, 15465601.
32. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. PEG IFN alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666-1672. 10.1056/NEJM200012073432301, 11106715.
33. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. PEG IFN alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047, 12324553.